Kidney Cancer News

This RSS feed URL is deprecated


This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news

Dr. Powles on the Impact of Immunotherapy in Kidney Cancer - OncLive



OncLive
 
Dr. Powles on the Impact of Immunotherapy in Kidney Cancer 
OncLive
Thomas Powles, MD, Barts Cancer Institute, discusses the impact of immunotherapy on the treatment landscape of kidney cancer. There has been an enormous change in the treatment of kidney cancer in 2017 with studies of immunotherapy in the frontline ...

 


FDA expands approval of Sutent to reduce the risk of kidney cancer returning - FDA.gov



WHBL Sheboygan
 
FDA expands approval of Sutent to reduce the risk of kidney cancer returning 
FDA.gov
The U.S. Food and Drug Administration today approved Sutent (sunitinib malate) for the adjuvant treatment of adult patients who are at a high risk of kidney cancer (renal cell carcinoma) returning after a kidney has been removed (nephrectomy). Adjuvant ...
FDA OKs First Adjuvant Treatment for Kidney Cancer Medscape
Pfizer: FDA Expands Approval Of Sutent To Reduce Risk Of Kidney Cancer Returning Nasdaq
FDA Expands Approval of Adjuvant Therapy for Adults at High Risk of Recurring Kidney Cancer Journal of Clinical Pathways

all 10 news articles » 


Dr. Capitanio Discusses Adjuvant Therapy for High-Risk Kidney ... - OncLive



OncLive
 
Dr. Capitanio Discusses Adjuvant Therapy for High-Risk Kidney ... 
OncLive
Umberto Capitanio, MD, FEBU, department of Urology, San Raffaele Scientific Institute, University Vita-Salute San Raffaele, discusses adjuvant therapy for ...

and more » 


Pfizer's Sutent kidney cancer win should give it a boost, at least until IO treatments arrive - FiercePharma



FiercePharma
 
Pfizer's Sutent kidney cancer win should give it a boost, at least until IO treatments arrive 
FiercePharma
Despite misgivings by an FDA advisory panel, the FDA Thursday approved Sutent to treat adult patients who are at a high risk of seeing their kidney cancer return after they have had a kidney removed. It is the first adjuvant treatment approved for ...
FDA Expands Approval of Kidney Cancer Treatment to Recurrence Prevention Pharmacy Times
FDA widens scope of Pfizer's Sutent in kidney cancer PharmaTimes
FDA expands approval for Pfizer cancer drug Sutent Reuters
Nasdaq  -Business Insider 
all 26 news articles » 


Dr. Volpe Discusses the Management of Localized Kidney Cancer - OncLive



OncLive
 
Dr. Volpe Discusses the Management of Localized Kidney Cancer 
OncLive
Alessandro Volpe, MD, University of Eastern Piedmont Hospital, Maggiore Della Carita Hospital, Novara, Italy, discusses the management of locally advanced kidney cancer. The management of localized kidney cancer has significantly changed over the last ...

 


Sutent gets FDA approval for early use in kidney cancer - PMLiVE



PMLiVE
 
Sutent gets FDA approval for early use in kidney cancer 
PMLiVE
Pfizer has been granted FDA approval for use of its Sutent drug to prevent recurrence in patients undergoing surgery for kidney cancer, around two months earlier than expected. The US regulator gave the nod to the drug late last week for adjuvant ...

 


Kidney Cancer: Non-Clear Cell Histology - OncLive - OncLive



OncLive
 
Kidney Cancer: Non-Clear Cell Histology - OncLive 
OncLive
James J. Hsieh, MD, PhD; Thomas Hutson, DO, PharmD, FACP; and Martin H. Voss, MD, review the ongoing clinical trials in patients with renal cell carcinoma ...

and more » 


KAEL confirms potential tracer as treatment for kidney cancer - Korea Biomedical Review



KAEL confirms potential tracer as treatment for kidney cancer 
Korea Biomedical Review
GemVax & KAEL said a research article that confirms the potential of GV1001 as a therapy to treat RCC (Renal Cell Carcinoma) was published in the online edition of international journal ?Urology? last Wednesday. A research team led by Professor Lee ...

 


Kidney Cancer: Vaccine-Based Approaches - OncLive



OncLive
 
Kidney Cancer: Vaccine-Based Approaches 
OncLive
Thomas Hutson, DO, PharmD, FACP: There is a clinical rationale to proceed with other immunologic types of therapy, such as vaccine strategies in kidney cancer. In order for a vaccine to be appropriate in kidney cancer, we need to overcome the innate ...

 


Novel Combinations in Kidney Cancer - OncLive



Novel Combinations in Kidney Cancer 
OncLive
The phase I study for this combination, which has been conducted across multiple solid tumor malignancies, has completed its accrual for kidney cancer patients, but the data for that have not been reported. The fact that the company has jumped right ...